Chris joined Samsara BioCapital in December of 2020. Previously, he was an SVP, Research for almost six years at Tekla Capital Management, the largest healthcare focused closed end fund manager where Chris covered the biotechnology and pharmaceutical sectors, both public and private and across all size companies. Prior to Tekla, Chris was a Partner/Head of Research for Merlin Biomed Private Equity/Merlin Nexus for 12 years. Merlin Nexus is a cross-over life sciences fund focused on negotiated transactions in both late-stage private and public companies. Prior to Merlin Nexus, Chris spent five years in the Allergy/Immunology Group at the Schering-Plough Research Institute. He has a B.S. in Cellular and Molecular Biology from Purchase College and both an M.S. in Biochemistry and an M.B.A. in Finance from NYU.